Fiche personne
Coordonnées
Institut Jean Godinot
1 rue du Général Koenig
51100 REIMS
0326504390
Territoire
Champagne-Ardenne
Statut
Hospitalier
Affiliation
Équipes/plateformes
Projets
Organoïdes dérivés de patientes et cancer du sein : conforter la pertinence d’un modèle préclinique intégrant le micro-environnement tumoral (ORGADINOT)
2023 - Porteur du projet : Dr VIGNOT Stéphane
Publications
Efficacy and cosmetic outcomes of high-dose-rate brachytherapy in the treatment of nasal carcinomas: a retrospective analysis.
Ettalhaoui L, Beddok A, Felici F, Assouly N, Brenet E, Roque A, Viguier M, Vignot S, Guilbert P, Da Silva Ribeiro Mota A
Int J Radiat Biol. 2025 09 23;:1-7
Towards a better understanding of patient expectations: ONCOPREMs-1 study-a qualitative study.
Diouri L, Ecarnot F, Berjot S, Popiolek A, Bouché O, Botsen D, Lemoine A, Vignot S, Barbe C
Aging Clin Exp Res. 2025 08 26;37(1):256
[Eclecticism and diversity, the issue volume of an ideal world].
Bay JO, Vignot S, Pourquier P, Mazure N
Bull Cancer. 2025 08 12;:
[Repotrectinib in advanced cancers with NTRK fusion after progression or not on a first TRK inhibitor].
Ventelou L, Vignot S
Bull Cancer. 2025 06 10;:
[Cross-looking visions of tomorrow's oncology].
Bay JO, Pourquier P, Vignot S, Mazure N
Bull Cancer. 2025 06;112(6):553-554
[Navigating the storm: scientific disputes, misinformation, ethical questioning].
Bay JO, Vignot S, Mazure N, Pourquier P
Bull Cancer. 2025 03 27;:
Improving Medical Education in Oncology: Enhancing Students' Understanding of Cancer Treatments Through Multidisciplinary Clinical Rotations.
Beddok A, Bouazzi L, Barbe C, Martin P, Gratiaux J, Guilbert P, Job L, Lemoine A, Morland D, Papathanassiou D, Perin S, Merrouche Y, Nifosi G, Soibinet P, Vignot S, Hotton J
J Cancer Educ. 2025 01 27;:
[In times of uncertainty…].
Vignot S, l'Allemain G, Pourquier P, Bay JO,
Bull Cancer. 2025 01;112(1):1-3
[Evaluating patient experience in oncology and chronic diseases: Critical analysis of available tools (PROMs, PREMs, Satisfaction)].
Diouri L, Barbe C, Vignot S
Bull Cancer. 2024 12 30;:
[A 2024 inventory in oncology news].
Vignot S, Bellesoeur A, Bouleuc C, Cohen R, Courtier B, De Nonneville A, Delom F, Evrard S, Firmin N, Gandemer V, Khettab M, Magné N, Orbach D, Pellier I, Rodrigues M, Wislez M, Bay JO
Bull Cancer. 2024 12 16;:
[Selpercatinib in advanced solid tumors with RET fusion, in the absence of therapeutic alternatives].
Helal C, Vignot S
Bull Cancer. 2024 12 9;:
Prise en charge des cancers thyroïdiens en 2024 : un numéro spécial exemplaire
Vignot S, Bay JO
Bull Cancer. 2024 10;111(10S1):10S1-10S2
Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.
Lerévérend C, Kotaich N, Cartier L, De Boni M, Lahire S, Fichel C, Thiebault C, Brabencova E, Maquin C, Barbosa E, Corsois L, Hotton J, Guendouzen S, Guilbert P, Lepagnol-Bestel AM, Cahen-Doidy L, Lehmann-Che J, Devy J, Bensussan A, Le Jan S, Pommier A, Merrouche Y, Le Naour R, Vignot S, Potteaux S
Int J Cancer. 2024 07 30;:
[Balancing drug regulation and health democracy: The role of patient and healthcare professional advisors at the ANSM].
Maison P, Bacon T, Daynes P, Decoene C, Mazet R, Vial T, Vignot S, Belgodère L, Oualikene-Gonin W, Ratignier-Carbonneil C
Therapie. 2024 06 22;:
Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
Invernizzi C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, Marques O, Munschi L, Marchand-Crety C, Jacquin N, Dubernard X, Beddok A, Lasset C, Assouly N, Vignot S, Brenet E
Oral Oncol. 2024 05 9;153:106833
[News, when you hold us…].
Bay JO, l'Allemain G, Pourquier P, Vignot S
Bull Cancer. 2024 02;111(2):127-128
[From 2023 to 2024: Consolidate our achievements, stay on course for innovation and progress].
Vignot S, Pourquier P, l'Allemain G, Bay JO,
Bull Cancer. 2024 01;111(1):1-2
Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience.
Belgodère L, Emmerich J, Albin N, Bacon T, Daynes P, Vignot S, Vial T, Renaud G, Le Saulnier C, Maillard-Couvreur C, Cachet M, Veyries ML, Youdarene R, Oualikene-Gonin W, Ratignier-Carbonneil C, Maison P
Front Public Health. 2023 11 17;11:1293110
Biomarkers of response to immunotherapy in early stage non-small cell lung cancer.
Roulleaux Dugage M, Albarrán-Artahona V, Laguna JC, Chaput N, Vignot S, Besse B, Mezquita L, Auclin E
Eur J Cancer. 2023 05;184:179-196
Clinical Trial Authorisation: A Final Look Back to Better Appraise the New European Regulation.
Vignot S, Guyader G, Salomon V, Vella P, Yoldjian I, Maison P, Ratignier-Carbonneil C
Rev Recent Clin Trials. 2023 ;18(3):167-171
Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study.
Debien V, Vignot S, Massard C, Malouf G, Hollebecque A, Scoazec JY, Michiels S, Verlingue L
Crit Rev Oncol Hematol. 2022 11 29;181:103888
Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority.
Vignot S, Dhanani A, Sainte-Marie I, de Ligniville Lajavardi L, Even G, Echemann M, Hulin N, Ménoret C, Maison P, Ratignier-Carbonneil C
Front Pharmacol. 2022 08 15;13:972660
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer.
Guyot D'Asnières De Salins A, Tachon G, Cohen R, Karayan-Tapon L, Junca A, Frouin E, Godet J, Evrard C, Randrian V, Duval A, Svrcek M, Lascols O, Vignot S, Coulet F, André T, Fléjou JF, Cervera P, Tougeron D
ESMO Open. 2021 06;6(3):100120
Collaboration Between Health-Care Professionals, Patients, and National Competent Authorities Is Crucial for Prevention of Health Risks Linked to the Inappropriate Use of Drugs: A Position Paper of the ANSM (Agence Nationale de Sécurité du Médicament et d
Vignot S, Daynes P, Bacon T, Vial T, Montagne O, Albin N, Emmerich J, Ratignier-Carbonneil C, Martin D, Maison P
Front Pharmacol. 2021 04 28;12:635841
[Clinical trials during pandemic crisis: How to ensure safety and maintain access to innovation].
Vignot S, Le Blaye O, Fluckiger L, Errard S, Marin B, Chapel E
Bull Cancer. 2020 06;107(6):617-619
[New prescription modalities for nominative premarket access: Tailored for infectiology].
Vignot S, Blaise T, Martin M
Med Mal Infect. 2020 06;50(4):386-387
New modalities of prescription of ATUns: Evolutions and revolution.
Vignot S, Plaine G, Chapel E
Rev Neurol (Paris). 2020 05;176(4):290-292
Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.
Vignot S, Martin M, Albin N, Schurtz C, Chapel E
Ann Oncol. 2019 11 1;30(11):1694-1696
[New prescription procedures for authorisations for temporary use: A key step for access to innovation].
Vignot S, Chapel E
Bull Cancer. 2019 11;106(11):943-945
[Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations].
Auvray M, Baylot C, Blanc-Durand F, Borcoman E, Pons-Tostivint E, Vignot S
Bull Cancer. 2018 11;105(11):1084-1093
[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, Vignot S
Bull Cancer. 2018 06 20;105(7-8):686-695
[Radiation therapy in inflammatory breast cancer].
Jardel P, Alami Z, Vignot S, Creisson A, Danhier S, Geffrelot J, Levy C, Kammerer E, Lebrun JF, Thariat J
Bull Cancer. 2018 04;105(4):415-425
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R
PLoS Comput Biol. 2018 02;14(2):e1005965
[HBV infection: Screening and treatment for oncology patients].
Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S
Bull Cancer. 2018 Feb;105(2):162-170
[Virus and cancer: Still hot topic].
L'Allemain G, Bay JO, Dutreix M, Vignot S
Bull Cancer. 2018 02;105(2):133-134
Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review.
Jardel P, Vignot S, Cutuli B, Creisson A, Vass S, Barranger E, Thariat J
Anticancer Res. 2018 01;38(1):23-31
[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].
Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO
Bull Cancer. 2018 01;105(1):6-14
Mechanisms of phosphenes in irradiated patients.
Mathis T, Vignot S, Leal C, Caujolle JP, Maschi C, Mauget-Faÿsse M, Kodjikian L, Baillif S, Herault J, Thariat J
Oncotarget. 2017 09 8;8(38):64579-64590
[Mobile applications for French medical students: Work in progress].
Vignot S, Servagi-Vernat S, Brouard B, Merrouche Y
Presse Med. 2017 Sep;:
[The breakthrough of personalized medicine, new hopes and new challenges].
Flippot R, Massard C, Auclin E, Azria D, Bourien H, Rochigneux P, Schernberg A, Verlingue L, Zafrani L, Vignot S
Bull Cancer. 2017 09;104(9):735-743
[What biomarkers for the future? The point of view of the residents in oncology after the ESMO 2016 Congress].
Auvray M, Benderra MA, Bretagne M, Faouzi S, Lebellec L, Majhoubi L, Saint-Ghislain M, Vignot S
Bull Cancer. 2017 09;104(9):744-751
[High-dose chemotherapy for tumor treatment: The beginning of the end?].
Bay JO, Vignot S
Bull Cancer. 2017 04;104(4):299-300
[Radiation-induced bronchiolitis obliterans with organizing pneumonia].
Ducray J, Vignot S, Lacout A, Pougnet I, Marcy PY, Chapellier C, Foray N, Creisson A, Thariat J
Cancer Radiother. 2017 04;21(2):148-154
[Obesity and cancer].
Salaün H, Thariat J, Vignot M, Merrouche Y, Vignot S
Bull Cancer. 2017 Jan;104(1):30-41
[Public health and political will: Convergence and divergence].
Vignot S, L'Allemain G, Bay JO,
Bull Cancer. 2017 ;104(7-8):597-598
[Which recent results in Oncology and Hematology will have an impact on our practices? The point of vue of Bulletin du Cancer editorial board].
Vignot S, André T, Gonçalves A, Guièze R, Magné N, Orbach D, Penel N, Thariat J, Wislez M, Bay JO
Bull Cancer. 2017 01;104(1):6-19
Mobile applications in oncology: is it possible for patients and healthcare professionals to easily identify relevant tools?
Brouard B, Bardo P, Bonnet C, Mounier N, Vignot M, Vignot S
Ann Med. 2016 11;48(7):509-515
[French guidelines and PubMed indexation].
Vignot S, L'Allemain G, Bay JO,
Bull Cancer. 2016 11;103(11):899-900
[Localized prostate cancer: Changes are still expected].
Vignot S, Bay JO, Massard C, Thariat J,
Bull Cancer. 2016 10;103(10):809-810
[French or English speaking publications: "À la carte"].
Vignot S, L'Allemain G, Bay JO,
Bull Cancer. 2016 09;103(9):709-10
[Prescription of high-cost medicines in French Hospitals: Regulation and procedures of reimbursement].
Wilkowsky C, Lenain A, Benbekhaled K, Le Gall MJ, Vignot S
Bull Cancer. 2016 04;103(4):353-60
[2015 through the eyes of the Bulletin of Cancer editorial board].
Magné N, Massard C, Bay JO, André T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Penel N, Rancoule C, Vignot S
Bull Cancer. 2016 01;103(1):3-17
[FGF/FGFR blockade: New insights in endometrial cancer].
Flippot R, Vignot S
Bull Cancer. 2015 12;102(12):964-5
[Nivolumab, a new hope in non-small cell lung cancer].
Flippot R, Fallet V, Besse B, Massard C, Wislez M, Vignot S
Bull Cancer. 2015 12;102(12):1046-52
[Non-small cell lung cancer: Remarkable developments].
Vignot S, Wislez M
Bull Cancer. 2015 12;102(12):962-3
Integrating genomics in head and neck cancer treatment: Promises and pitfalls.
Thariat J, Vignot S, Lapierre A, Falk AT, Guigay J, Van Obberghen-Schilling E, Milano G
Crit Rev Oncol Hematol. 2015 09;95(3):397-406
[Mobile applications in oncology available for French users: Who's behind?].
Brouard B, Bardo P, Bonnet C, Vignot M, Vignot S
Bull Cancer. 2015 09;102(9):716-8
[Abiraterone: Overall survival benefit and subsidiary issues].
Vignot S
Bull Cancer. 2015 06;102(6):487-8
[Brilliant, precise, compelling, controversial...].
Vignot S, Bay JO
Bull Cancer. 2015 06;102(6 Suppl 1):S1
[FGF/FGFR signalling: Implication in oncogenesis and perspectives].
Flippot R, Kone M, Magné N, Vignot S
Bull Cancer. 2015 06;102(6):516-26
[Molecular targeted therapies and cytotoxics: Friends or foes?].
Vignot S, Zalcman G
Bull Cancer. 2015 06;102(6 Suppl 1):S91-2
Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
Vignot S, Lefebvre C, Frampton GM, Meurice G, Yelensky R, Palmer G, Capron F, Lazar V, Hannoun L, Miller VA, André F, Stephens PJ, Soria JC, Spano JP
Eur J Cancer. 2015 05;51(7):791-9
[Adjuvant chemotherapy for stage I lung cancer in the elderly].
Vignot S
Bull Cancer. 2015 05;102(5):401-2
[2015, an evolution without revolution, a change within continuity].
Bay JO, L'Allemain G, Massard C, Vignot S,
Bull Cancer. 2015 01;102(1):2-3
[Major advances in oncology in 2014: the editorial board of the Bulletin du Cancer point of view].
Massard C, Bay JO, André T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Magné N, Vignot S
Bull Cancer. 2015 01;102(1):92-104
[Recent evolutions in metastatic melanoma].
Massard C, Lebbé C, Vignot S
Bull Cancer. 2014 12;101 Suppl 2:S3-4
[eHealth and mHealth: current developments in 2014 and perspectives in oncology].
Brouard B, Bardo P, Vignot M, Bonnet C, Vignot S
Bull Cancer. 2014 Oct;101(10):940-50
